Ademi LLP Investigates BioLife Solutions Transaction with Repligen

Law firm Ademi LLP announced on July 22, 2026, that it is investigating BioLife Solutions (NASDAQ: BLFS) for potential breaches of fiduciary duty and other violations of law related to its recently announced transaction with Repligen.

The agreement stipulates that BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share. This values each BioLife share at approximately $31.00, placing the total enterprise value of the transaction at around $1.5 billion. The deal's consideration is structured as 36% cash and 64% Repligen stock.

Ademi LLP's investigation will center on the conduct of BioLife's board of directors. The law firm stated that the transaction agreement includes provisions that limit competing transactions by imposing a significant penalty if BioLife accepts an alternative bid.

According to the press release, BioLife insiders are expected to receive substantial benefits through change of control arrangements. Ademi LLP specializes in shareholder litigation. The firm invites BioLife shareholders to contact them for additional information regarding the investigation.